CA
GMAB icon

Continuum Advisory’s Genmab GMAB Stock Holding History

Continuum Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27
Closed -$529 – 858
2025
Q1 		$529 Sell
27
-19
-41% -$399 ﹤0.01% 1572
2024
Q4 		$960 Buy
46
+1
+2% +$22 ﹤0.01% 1627
2024
Q3 		$953 Buy
45
+27
+150% +$722 ﹤0.01% 1631
2024
Q2 		$452 Hold
18
– – ﹤0.01% 1615
2024
Q1 		$519 Buy
+18
New +$529 ﹤0.01% 1598

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Continuum Advisory's GMAB Position: Q2 2025 in Review

Continuum Advisory sold out of Genmab (GMAB) in Q2 2025, closing a stake of 27 shares — an estimated $529 sold.

Continuum Advisory first reported a position in GMAB in Q1 2024 and held it in 5 quarters. The position peaked at $960 in Q4 2024. 217 funds tracked by Wall St. Rank hold GMAB as of Q2 2025.

  • Continuum Advisory reported no remaining Genmab position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 27 Genmab shares in Q2 2025, an estimated $529.
  • Continuum Advisory first reported a position in Genmab in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Genmab position peaked at $960 in Q4 2024.
  • 217 funds tracked by Wall St. Rank held Genmab as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.